A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

Stopped early · Phase 2

Conditions studied: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2

In brief

Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.

Key facts

Study ID

NCT00437164

Run by

GlaxoSmithKline

People needed

1

Starts

2006-09-01

Expected to finish

2006-11-01

Last updated by the study team

2012-06-04

Who can join

Age: 30 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have been diagnosed by a doctor with Type 2 Diabetes Mellitus at least 3 months before Screening
• Have a body mass index within range 25 to 40.0kg/m2 inclusive
• Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition)

You may not qualify if…

• Significant weight loss or gain in the 3 months before screening
• Have used insulin to treat hyperglycemia within 3 months before screening
• Have a history of fluid retention
• Have uncontrolled high blood pressure
• Have liver disease
• Take loop diuretics (water pills), certain blood thinners, and/or St. Johns Wort. - Have or have had certain kinds of cancer

Where it is running

• GSK Investigational Site — Beverly Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.